{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:49:23Z","timestamp":1781660963651,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jpba.2025.116906","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T15:52:21Z","timestamp":1744905141000},"page":"116906","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Positional isoform analysis of PEGylated biotherapeutic protein using a novel peptide-based reversed-phase liquid chromatography with UV detection"],"prefix":"10.1016","volume":"263","author":[{"given":"Min","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jielun","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingwu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2025.116906_bib1","article-title":"Protein PEGylation: navigating recombinant protein stability, aggregation, and bioactivity","volume":"25","author":"Zuma","year":"2022","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.jpba.2025.116906_bib2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1021\/acsbiomaterials.3c00253","article-title":"PEGylation of human vascular endothelial growth factor","volume":"10","author":"Wolkersdorfer","year":"2023","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.jpba.2025.116906_bib3","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2174\/1381612043452613","article-title":"The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta\u00ae)","volume":"10","author":"Molineux","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jpba.2025.116906_bib4","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1016\/S0021-9258(17)40291-2","article-title":"Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol","volume":"252","author":"Abuchowski","year":"1977","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jpba.2025.116906_bib5","first-page":"242","article-title":"Obstacles and pitfalls in the PEGylation of therapeutic proteins","volume":"11","author":"Gaberc-Porekar","year":"2008","journal-title":"Curr. Opin. Drug Discov. Dev."},{"key":"10.1016\/j.jpba.2025.116906_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.717326","article-title":"Purification of modified therapeutic proteins available on the market: an analysis of chromatography-based strategies","volume":"9","author":"Sanchez-Trasvina","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jpba.2025.116906_bib7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jconrel.2014.02.002","article-title":"Process for protein PEGylation","volume":"180","author":"Pfister","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jpba.2025.116906_bib8","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1039\/c1py00034a","article-title":"FDA-approved poly(ethylene glycol)-protein conjugate drugs","volume":"2","author":"Alconcel","year":"2011","journal-title":"Polym. Chem."},{"key":"10.1016\/j.jpba.2025.116906_bib9","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0169-409X(02)00028-5","article-title":"Use of peginterferon alfa-2a (40 KD) (Pegasys\u00ae) for the treatment of hepatitis C","volume":"54","author":"Reddy","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jpba.2025.116906_bib10","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.xphs.2015.11.015","article-title":"PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs","volume":"105","author":"Turecek","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2025.116906_bib11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jbiotec.2009.05.012","article-title":"Enhanced circulation half-life of site-specific PEGylated rhG-CSF: optimization of PEG molecular weight","volume":"142","author":"Zhai","year":"2009","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.jpba.2025.116906_bib12","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jpba.2025.116906_bib13","doi-asserted-by":"crossref","first-page":"25831","DOI":"10.3390\/ijms161025831","article-title":"Site-specific PEGylation of therapeutic proteins","volume":"16","author":"Dozier","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jpba.2025.116906_bib14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0142-9612(00)00193-9","article-title":"Peptide and protein PEGylation: a review of problems and solutions","volume":"22","author":"Veronese","year":"2001","journal-title":"Biomaterials"},{"key":"10.1016\/j.jpba.2025.116906_bib15","first-page":"635","article-title":"Amino acid-mPEGs: promising excipients to stabilize human growth hormone against aggregation","volume":"26","author":"Vakili","year":"2023","journal-title":"Iran. J. Basic Med. Sci."},{"key":"10.1016\/j.jpba.2025.116906_bib16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.tibtech.2010.02.001","article-title":"Recent advances in large-scale production of monoclonal antibodies and related proteins","volume":"28","author":"Shukla","year":"2010","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jpba.2025.116906_bib17","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1006\/abio.1997.2128","article-title":"Positional isomers of monopegylated interferon \u03b1-2a: isolation, characterization, and biological activity","volume":"247","author":"Monkarsh","year":"1997","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jpba.2025.116906_bib18","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/j.ddtec.2009.02.002","article-title":"PEGylation: posttranslational bioengineering of protein biotherapeutics","volume":"5","author":"Veronese","year":"2008","journal-title":"Drug Discov. Today.: Technol."},{"key":"10.1016\/j.jpba.2025.116906_bib19","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1023\/A:1016113117851","article-title":"Preparation and characterization of mono-PEGylated epidermal growth factor: evaluation of in vitro biologic activity","volume":"19","author":"Lee","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpba.2025.116906_bib20","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1021\/bc049843w","article-title":"Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins","volume":"15","author":"Fee","year":"2004","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jpba.2025.116906_bib21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jpba.2025.116906_bib22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/978-1-61779-921-1_22","article-title":"Characterization of PEGylated biopharmaceutical products by LC\/MS and LC\/MS\/MS","volume":"899","author":"Huang","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jpba.2025.116906_bib23","doi-asserted-by":"crossref","first-page":"10848","DOI":"10.1021\/acs.analchem.6b03577","article-title":"Characterization of the reversed-phase chromatographic behavior of PEGylated peptides based on the poly(ethylene glycol) dispersity","volume":"88","author":"Park","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2025.116906_bib24","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/13696998.2021.1922252","article-title":"Biosimilar pegfilgrastim may offer affordable treatment options for patients in France: a budget impact analysis on the basis of clinical trial and real-world data","volume":"24","author":"Yang","year":"2021","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jpba.2025.116906_bib25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.biologicals.2015.05.012","article-title":"Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein","volume":"43","author":"McCue","year":"2015","journal-title":"Biologicals"},{"key":"10.1016\/j.jpba.2025.116906_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.chroma.2004.10.062","article-title":"Chromatographic separation and mass spectrometric identification of positional isomers of polyethylene glycol-modified growth hormone-releasing factor (1-29)","volume":"1061","author":"Youn","year":"2004","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2025.116906_bib27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.chroma.2012.10.047","article-title":"Isoform separation and binding site determination of mono-PEGylated lysozyme with pH gradient chromatography","volume":"1268","author":"Maiser","year":"2012","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2025.116906_bib28","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jchromb.2016.12.014","article-title":"Isoform separation and structural identification of mono-PEGylated recombinant human growth hormone (PEG-rhGH) with pH gradient chromatography","volume":"1044-1045","author":"Qin","year":"2017","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2025.116906_bib29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jpba.2015.02.037","article-title":"Ion-exchange chromatography for the characterization of biopharmaceuticals","volume":"113","author":"Fekete","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.116906_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2023.125062","article-title":"Characterization of charge variants, including post-translational modifications and proteoforms, of bispecific antigen-binding protein by cation-exchange chromatography coupled to native mass spectrometry","volume":"266","author":"Shah","year":"2024","journal-title":"Talanta"},{"key":"10.1016\/j.jpba.2025.116906_bib31","first-page":"183","article-title":"The Dansyl-Edman method for manual peptide sequencing","volume":"64","author":"Walker","year":"1997","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jpba.2025.116906_bib32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ijbiomac.2010.01.017","article-title":"Characterization of a monoPEG20000-Endostar","volume":"46","author":"Tong","year":"2010","journal-title":"Int. J. Biol. Macromol."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852500247X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852500247X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T02:21:21Z","timestamp":1747966881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170852500247X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":32,"alternative-id":["S073170852500247X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116906","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Positional isoform analysis of PEGylated biotherapeutic protein using a novel peptide-based reversed-phase liquid chromatography with UV detection","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116906","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116906"}}